CN114457102A - Gene expression cassette for encoding secretory Mersacidin and preparation method thereof - Google Patents
Gene expression cassette for encoding secretory Mersacidin and preparation method thereof Download PDFInfo
- Publication number
- CN114457102A CN114457102A CN202210173000.6A CN202210173000A CN114457102A CN 114457102 A CN114457102 A CN 114457102A CN 202210173000 A CN202210173000 A CN 202210173000A CN 114457102 A CN114457102 A CN 114457102A
- Authority
- CN
- China
- Prior art keywords
- gene
- mersacidin
- primer
- expression cassette
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010067215 mersacidin Proteins 0.000 title claims abstract description 63
- 230000014509 gene expression Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- JSWKNDSDVHJUKY-CYGWNLPQSA-N mersacidin Chemical compound C([C@@H](C(=O)N[C@@H]1[C@H](C)SC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H]1[C@H](C)SC[C@H]2C(=O)N[C@H](C(N/C=C/S[C@@H](C)C(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)[C@H](C)CC)NC(=O)[C@H]1[C@@H](SC[C@H](N)C(=O)N1)C)C1=CC=CC=C1 JSWKNDSDVHJUKY-CYGWNLPQSA-N 0.000 title claims abstract 9
- 230000003248 secreting effect Effects 0.000 title claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims description 31
- 230000004151 fermentation Effects 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 20
- 238000003259 recombinant expression Methods 0.000 claims description 15
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 101100024316 Bacillus sp. (strain HIL-Y85/54728) mrsD gene Proteins 0.000 claims description 9
- 101100090763 Escherichia coli (strain K12) rlmE gene Proteins 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 235000019764 Soybean Meal Nutrition 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000004455 soybean meal Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108091008053 gene clusters Proteins 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 238000010367 cloning Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 230000002335 preservative effect Effects 0.000 abstract description 2
- 239000000273 veterinary drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- JSWKNDSDVHJUKY-MNVIWFPGSA-N CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 Chemical compound CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 JSWKNDSDVHJUKY-MNVIWFPGSA-N 0.000 description 52
- 239000013598 vector Substances 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 241000193468 Clostridium perfringens Species 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000194103 Bacillus pumilus Species 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000003114 Bacillus velezensis FZB42 Species 0.000 description 1
- 241001470651 Clostridium perfringens ATCC 13124 Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- ULXTYUPMJXVUHQ-OVTFQNCVSA-N lipid II Chemical compound OC(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@@H](OP(O)(=O)OP(O)(=O)OC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(\C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ULXTYUPMJXVUHQ-OVTFQNCVSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明属于基因工程领域,具体涉及用于编码分泌型Mersacidin的基因表达盒及其制备方法。The invention belongs to the field of genetic engineering, in particular to a gene expression cassette for encoding secreted Mersacidin and a preparation method thereof.
技术背景technical background
细菌素是细菌在代谢过程中通过核糖体合成的一类具有抑菌活性的多肽或前体多肽,有着理想的益生菌特性,其具备有效抑制病原体、调节炎症、促进伤口愈合和粘膜防御等功能,且不易产生耐药性的特点。Bacteriocins are a class of polypeptides or precursor polypeptides with bacteriostatic activity that are synthesized by bacteria through ribosomes during metabolism. They have ideal probiotic properties and can effectively inhibit pathogens, regulate inflammation, and promote wound healing and mucosal defense. , and is not easy to develop drug resistance characteristics.
Mersacidin由Bacillus HIL Y-8554728产生,长20aa,属于Ib类细菌素。Mersacidin纯品为白色非晶粉末,在环境温度下稳定,pH 5.0~7.0稳定,不溶于水;金属盐易溶于水,且能增强其杀菌活性。Mersacidin通过与肽聚糖前体lipid II的糖磷酸基团形成复合物,抑制肽聚糖生物合成的转糖基化反应,从而抑制细胞壁合成杀灭微生物。Mersacidin对耐甲氧西林金黄色葡萄球菌(MRSA)的MIC为1~32μg/mL,对耐甲氧西林表皮葡萄球菌的MIC为0.5~16μg/mL,对链球菌的MIC为0.5~8μg/mL,对产气荚膜梭菌的MIC为0.5~8μg/mL。虽然mersacidin对MRSA的MIC大于万古霉素,但给MRSA(St.aureus E710)攻毒小鼠皮下注射25mg/kg Mersacidin进行治疗,治愈率达100%,而相同剂量万古霉素治疗组的存活率仅有67%。此外,Mersacidin经腹腔给药可以清除小鼠鼻炎模型中经鼻腔接种的MRSA菌株。以上证据证实,尽管Mersacidin体外MIC较高,但体内效果很好,具有开发成抗菌药物的潜力。Mersacidin is produced by Bacillus HIL Y-8554728, is 20aa long, and belongs to class Ib bacteriocin. Pure Mersacidin is white amorphous powder, stable at ambient temperature, stable at pH 5.0-7.0, insoluble in water; metal salts are easily soluble in water and can enhance its bactericidal activity. Mersacidin inhibits the transglycosylation reaction of peptidoglycan biosynthesis by forming a complex with the sugar phosphate group of peptidoglycan precursor lipid II, thereby inhibiting cell wall synthesis and killing microorganisms. The MIC of Mersacidin against methicillin-resistant Staphylococcus aureus (MRSA) is 1-32 μg/mL, the MIC against methicillin-resistant Staphylococcus epidermidis is 0.5-16 μg/mL, and the MIC against Streptococcus is 0.5-8 μg/mL , the MIC to Clostridium perfringens is 0.5~8μg/mL. Although the MIC of mersacidin against MRSA is greater than that of vancomycin, subcutaneous injection of 25 mg/kg mersacidin in MRSA (St. aureus E710)-challenged mice resulted in a 100% cure rate, while the survival rate of the same dose of vancomycin treatment group Only 67%. In addition, intraperitoneal administration of Mersacidin can eliminate nasally inoculated MRSA strains in a mouse model of rhinitis. The above evidence confirms that Mersacidin is effective in vivo despite its high MIC in vitro and has the potential to be developed into an antibacterial drug.
Mersacidin是由一个包括转录、翻译、运输和修饰等多个相关基因组成的基因簇AJ250862.2来合成的。该基因簇长12324bp,由10个ORF组成,由mrsA编码68个残基的前肽,前肽mrsA被mrsD脱羧和氧化,在C端半胱氨酸产生2-硫代乙胺功能。被修饰的mrsA作为mrsM产生四环结构的底物,经mrsT加工后分泌成为最终的生物活性化合物。其中有一个调控基因mrsR1,负责控制mrsA的合成;还有一个双组分系统mrsR2/mrsK2,编码参与诱导免疫基因mrsE、mrsF和mrsG的传感器和激酶。Bacillus amyloliquefaciens FZB42作为宿主菌外源表达Mersacidin已获得成功,但表达量较低。这说明外源表达Mersacidin是可行的,问题在于如何提高表达量,主要是如何提高表达菌株对Mersacidin的耐受性。Mersacidin is synthesized from a gene cluster AJ250862.2, which includes transcription, translation, transport and modification genes. The gene cluster is 12324 bp long and consists of 10 ORFs, which encode a 68-residue propeptide by mrsA, which is decarboxylated and oxidized by mrsD to generate a 2-thioethylamine function at the C-terminal cysteine. The modified mrsA serves as a substrate for the formation of a tetracyclic structure by mrsM, which is processed by mrsT and secreted into the final biologically active compound. Among them is a regulatory gene, mrsR1, responsible for the synthesis of mrsA; and a two-component system, mrsR2/mrsK2, which encodes sensors and kinases involved in the induction of immune genes mrsE, mrsF, and mrsG. Bacillus amyloliquefaciens FZB42 has been successfully used as a host to express Mersacidin, but the expression level is low. This shows that exogenous expression of Mersacidin is feasible. The problem is how to increase the expression level, mainly how to improve the tolerance of expression strains to Mersacidin.
发明内容SUMMARY OF THE INVENTION
为解决上述问题,本发明利用高保真酶扩增Mersacidin基因簇基因mrsK2R2FGEAR1DMT的mrsK2R2FGE、mrsAR1D、和mrsMT,再利用Gibson克隆技术将Mersacidin基因簇3段基因连接,构建成Mersacidin表达盒,该表达盒置于强启动子的下游,将其导入基因工程菌Bacillus subtilis SCK168中实现Mersacidin的高效分泌表达,为饲料添加剂、兽药、食品及医药提供一种廉价的生物抗菌剂和防腐剂。In order to solve the above problems, the present invention uses high-fidelity enzymes to amplify mrsK2R2FGE, mrsAR1D, and mrsMT of the Mersacidin gene cluster gene mrsK2R2FGEAR1DMT, and then uses Gibson cloning technology to connect the three segments of the Mersacidin gene cluster to construct a Mersacidin expression cassette. In the downstream of the strong promoter, it was introduced into the genetically engineered bacteria Bacillus subtilis SCK168 to realize the efficient secretion and expression of Mersacidin, which provides a cheap biological antibacterial agent and preservative for feed additives, veterinary drugs, food and medicine.
本发明的目的之一,在于提供一种用于编码分泌型Mersacidin的基因表达盒。One of the objects of the present invention is to provide a gene expression cassette for encoding secreted Mersacidin.
为实现上述目的,本发明采取以下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
所述基因表达盒采用克隆扩增技术得到三个克隆片段:基因mrsK2R2FGE、基因mrsAR1D和基因mrsMT;所述基因mrsK2R2FGE为片段1,由mrsK2蛋白编码的基因mrsK2、mrsR2蛋白编码的基因mrsR2、mrsF蛋白编码的基因mrsF、mrsG蛋白编码的基因mrsG和mrsE蛋白编码的基因mrsE组成,所述基因mrsAR1D为片段2,由前肽mrsA编码的基因mrsA、mrsR1蛋白编码的基因mrsR1和mrsD蛋白编码的基因mrsD组成,所述基因mrsMT为片段3,由mrsM蛋白编码的基因mrsM和mrsT蛋白编码的基因mrsT组成。The gene expression cassette adopts cloning amplification technology to obtain three cloned fragments: gene mrsK2R2FGE, gene mrsAR1D and gene mrsMT; the gene mrsK2R2FGE is
进一步,所述三个克隆片段分别选用引物G1和引物G2克隆片段1,选用引物G3和引物G4克隆片段2,选用引物G5和引物G6克隆片段3;所述引物G1的核苷酸序列如SEQ ID NO.2所示,所述引物G2的核苷酸序列如SEQ ID NO.3所示,所述引物G3的核苷酸序列如SEQ IDNO.4所示,所述引物G4的核苷酸序列如SEQ ID NO.5所示,所述引物G5的核苷酸序列如SEQID NO.6所示,所述引物G6的核苷酸序列如SEQ ID NO.7所示。Further, the three cloned fragments select primer G1 and primer
进一步,所述基因表达盒,其核苷酸序列如SEQ ID NO.1所示。Further, the nucleotide sequence of the gene expression cassette is shown in SEQ ID NO.1.
进一步,所述基因表达盒从5’端到3’端依次为:mrsK2蛋白编码的基因mrsK2、mrsR2蛋白编码的基因mrsR2、mrsF蛋白编码的基因mrsF、mrsG蛋白编码的基因mrsG、mrsE蛋白编码的基因mrsE、前肽mrsA编码的基因mrsA、mrsR1蛋白编码的基因mrsR1、mrsD蛋白编码的基因mrsD、mrsM蛋白编码的基因mrsM、mrsT蛋白编码的基因mrsT。Further, the gene expression cassettes are sequentially from the 5' end to the 3' end: the gene mrsK2 encoded by the mrsK2 protein, the gene mrsR2 encoded by the mrsR2 protein, the gene mrsF encoded by the mrsF protein, and the gene encoded by the mrsG protein are encoded by the mrsG and mrsE proteins. The gene mrsE, the gene mrsA encoded by the propeptide mrsA, the gene mrsR1 encoded by the mrsR1 protein mrsR1, the mrsD protein encoded gene mrsD, the mrsM protein encoded gene mrsM, and the mrsT protein encoded gene mrsT.
进一步,表达盒基因序列共计12324bp:1到1440为基因mrsK2;1437到2159基因mrsR2;2402到3313基因mrsF;3310到4068基因mrsG;4085到4819基因mrsE;5104到5310基因mrsA;5406到6047基因mrsR1;6096到6680基因mrsD;6892到10080基因mrsM;10132到12324基因mrsT。Further, the gene sequence of the expression cassette is 12324 bp in total: 1 to 1440 are mrsK2; 1437 to 2159 are mrsR2; 2402 to 3313 are mrsF; 3310 to 4068 are mrsG; 4085 to 4819 are mrsE; 5104 to 5310 are mrsA; mrsR1; 6096 to 6680 genes mrsD; 6892 to 10080 genes mrsM; 10132 to 12324 genes mrsT.
进一步,所述的基因表达盒包括启动子,启动子3’端连接前肽编码基因mrsA。Further, the gene expression cassette includes a promoter, and the 3' end of the promoter is connected to the propeptide-encoding gene mrsA.
本发明的目的之二,在于提供一种重组表达载体,该重组表达载体可以实现分泌型Mersacidin的表达。The second object of the present invention is to provide a recombinant expression vector, which can realize the expression of secreted Mersacidin.
为实现上述目的,本发明采取以下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
所述重组表达载体包含上述的基因表达盒。The recombinant expression vector comprises the above-mentioned gene expression cassette.
进一步,所述重组表达载体为质粒载体或病毒载体。Further, the recombinant expression vector is a plasmid vector or a viral vector.
进一步,所述病毒载体为慢病毒载体、腺相关病毒载体或腺病毒载体。Further, the viral vector is a lentiviral vector, an adeno-associated viral vector or an adenoviral vector.
进一步,作为一种优选,所述质粒载体为pP43NMK载体。Further, as a preference, the plasmid vector is pP43NMK vector.
进一步,此重组表达载体包括但不仅限于pP43NMK载体,其他的带有启动子和信号肽的芽孢杆菌表达载体,也可以构建含有分泌型Mersacidin表达盒“启动子-mersacidin”的载体。Further, this recombinant expression vector includes but is not limited to pP43NMK vector, other Bacillus expression vectors with promoter and signal peptide, and a vector containing secreted Mersacidin expression cassette "promoter-mersacidin" can also be constructed.
本发明的目的之三,在于提供一种基因工程菌,该基因工程菌经培养后表达量高于野生菌,而且发酵培养基成本低、发酵周期短、易于产业化。The third object of the present invention is to provide a genetically engineered bacterium, the genetically engineered bacterium has a higher expression level than wild bacterium after culture, and the fermentation medium cost is low, the fermentation period is short, and the industrialization is easy.
为实现上述目的,本发明采取以下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
所述基因工程菌包含上述的基因表达盒或上述的重组表达载体。The genetically engineered bacteria comprise the above-mentioned gene expression cassette or the above-mentioned recombinant expression vector.
进一步,作为一种优选,所述基因工程菌为Bacillus subtilis SCK168。Further, as a preference, the genetically engineered bacteria is Bacillus subtilis SCK168.
进一步,所述Bacillus subtilis SCK168的培养基组分包括:豆粕粉10±5g/L,酵母粉10±5g/L,蛋白胨10±5g/L,葡萄糖10±5g/L,氯化钠5±2g/L。Further, the medium components of Bacillus subtilis SCK168 include:
进一步,此基因工程菌包括但不仅限于Bacillus subtilis,其他的基因工程菌如地衣芽孢杆菌、短小芽孢杆菌也可以实现载体的转化与表达。Further, the genetically engineered bacteria include but are not limited to Bacillus subtilis, and other genetically engineered bacteria such as Bacillus licheniformis and Bacillus pumilus can also achieve vector transformation and expression.
本发明的目的之四,在于提供一种分泌型Mersacidin的制备方法,该方法培养成本低,产量高,为实现Mersacidin产业化生产提供了新的方向和思路。The fourth purpose of the present invention is to provide a method for preparing secreted Mersacidin, which has low culture cost and high yield, and provides a new direction and idea for realizing the industrialized production of Mersacidin.
为实现上述目的,本发明采取以下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
基于一种分泌型Mersacidin的制备方法,具体包括以下步骤:Based on a preparation method of secreted Mersacidin, it specifically includes the following steps:
1)构建上述的重组表达载体;1) construct the above-mentioned recombinant expression vector;
2)将上述的重组表达载体转入上述的基因工程菌中;2) the above-mentioned recombinant expression vector is transferred into the above-mentioned genetically engineered bacteria;
3)筛选阳性重组子在培养基中发酵培养。3) Screen the positive recombinants and ferment them in the medium.
进一步,所述分泌型Mersacidin的制备方法还可以包括以下步骤:Further, the preparation method of the secreted Mersacidin may further comprise the following steps:
4)取发酵液测定其抑菌活性和含量;4) get the fermentation broth to measure its antibacterial activity and content;
5)测定发酵液的抑菌效果,检测抑菌活性;5) Measure the bacteriostatic effect of the fermentation broth, and detect the bacteriostatic activity;
6)将发酵液过滤,用高效液相法测定其含量。6) Filter the fermentation broth and measure its content by high performance liquid phase method.
本发明的目的之五,在于获得一种通过上述制备方法得到的分泌型Mersacidin。The fifth object of the present invention is to obtain a secreted Mersacidin obtained by the above preparation method.
本发明的有益之处在于:The benefits of the present invention are:
1.本发明获得的分泌型Mersacidin为随机结构,其活性好,生物稳定性强,对热、胃液肠液等具有很好的耐受性,抑菌效果显著。1. The secreted Mersacidin obtained by the present invention has a random structure, and has good activity, strong biological stability, good tolerance to heat, gastric juice and intestinal juice, etc., and has a remarkable bacteriostatic effect.
2.本发明获得的Mersacidin表达盒载体“启动子-mrsK2R2FGE-mrsAR1D-mrsMT基因”,通过对Mersacidin基因簇编码基因的组合,实现了Mersacidin的合成并运输到胞外分泌表达。2. The Mersacidin expression cassette vector "promoter-mrsK2R2FGE-mrsAR1D-mrsMT gene" obtained in the present invention realizes the synthesis of Mersacidin and transports it to extracellular secretion and expression by combining the genes encoding the Mersacidin gene cluster.
3.本发明公开了一种分泌型Mersacidin的制备方法,该方法培养成本低,产量高,为实现Mersacidin产业化生产提供了新的方向和思路。3. The present invention discloses a method for preparing secreted Mersacidin, which has low culture cost and high yield, and provides a new direction and idea for realizing the industrialized production of Mersacidin.
4.本发明用Gibson克隆技术将mrsK2R2FGE、mrsAR1D和mrsMT基因片段连接于带有启动子的表达载体上,构建Mersacidin表达盒载体“启动子-mrsK2R2FGE-mrsAR1D-mrsMT基因”。因载体上有mrsR1DMT能够对前肽进行加工修饰和转运,实现了Mersacidin的合成并运输到胞外分泌表达。4. The present invention uses Gibson cloning technology to connect mrsK2R2FGE, mrsAR1D and mrsMT gene fragments to an expression vector with a promoter to construct a Mersacidin expression cassette vector "promoter-mrsK2R2FGE-mrsAR1D-mrsMT gene". Because the mrsR1DMT on the carrier can process, modify and transport the propeptide, the synthesis and transport of Mersacidin to extracellular secretion and expression are realized.
5.本发明将含有Mersacidin表达盒的重组表达载体转化入基因工程菌中构建成菌株。菌株在相关培养基中培养,通过测定抑菌圈来判断其活性,采用HPLC测定Mersacidin在Bacillus subtilis中的表达量。该表达系统的Mersacidin表达量高于野生菌,而且发酵培养基成本低、发酵周期短、易于产业化。5. The present invention transforms the recombinant expression vector containing the Mersacidin expression cassette into genetically engineered bacteria to construct a strain. The strains were cultured in the relevant medium, and their activity was judged by measuring the inhibition zone. The expression of Mersacidin in Bacillus subtilis was determined by HPLC. The expression level of Mersacidin of the expression system is higher than that of wild bacteria, and the fermentation medium cost is low, the fermentation period is short, and the industrialization is easy.
6.本发明首次利用基因工程和发酵工程发酵表达Mersacidin,利用安全菌株Bacillus subtilis SCK168作为表达宿主菌,带有启动子P43的pP43NMK表达载体,对Mersacidin基因簇AJ250862.2进行重组,将表达盒mersacidin与pP43NMK构建表达载体。本发明表达的Mersacidin具有高活性,提高Mersacidin在Bacillus subtilis中的分泌表达水平,有利于应用推广。6. The present invention utilizes genetic engineering and fermentation engineering to ferment and express Mersacidin for the first time. The safe strain Bacillus subtilis SCK168 is used as the expression host, the pP43NMK expression vector with promoter P43 is used to recombine the Mersacidin gene cluster AJ250862.2, and the expression cassette mersacidin is recombined. An expression vector was constructed with pP43NMK. The Mersacidin expressed in the invention has high activity, improves the secretion and expression level of Mersacidin in Bacillus subtilis, and is beneficial to application and popularization.
7.本发明所述制备方法生产的分泌型Mersacidin表达水平高达1.26g/L,高于目前所有报道中的Mersacidin表达水平。7. The expression level of secreted Mersacidin produced by the preparation method of the present invention is as high as 1.26 g/L, which is higher than the expression level of Mersacidin in all current reports.
附图说明Description of drawings
图1为重组表达载体的构建过程;Fig. 1 is the construction process of recombinant expression vector;
图2为发酵液对产气荚膜梭菌的抑菌活性(A:Bacillus subtilis SCK168发酵液上清;B:Bacillus subtilis MRS08发酵液上清;C:Bacillus subtilis MRS24发酵液上清;D:100ng万古霉素);Figure 2 shows the bacteriostatic activity of the fermentation broth against Clostridium perfringens (A: Bacillus subtilis SCK168 fermentation broth supernatant; B: Bacillus subtilis MRS08 fermentation broth supernatant; C: Bacillus subtilis MRS24 fermentation broth supernatant; D: 100ng Vancomycin);
图3为Mersacidin纯品(A)和发酵液(B)的高效液相图谱。Figure 3 is the high performance liquid phase diagram of pure Mersacidin (A) and fermentation broth (B).
具体实施方式Detailed ways
下面将结合具体的实施例对本发明的技术方案进行更进一步地清楚、完整地描述。显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部实施例。因此,基于本发明中的实施例,本领域技术人员在没有付出创造性劳动前提下所获得的其他所有实施例都属于本发明的保护范围。The technical solutions of the present invention will be further clearly and completely described below with reference to specific embodiments. Obviously, the described embodiments are only some, but not all, embodiments of the present invention. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts fall within the protection scope of the present invention.
实施例1.重组载体的构建Example 1. Construction of recombinant vector
1)将载体pP43NMK(BioVector NTCC Inc.)用HindIII和PstI进行双酶切。1) The vector pP43NMK (BioVector NTCC Inc.) was double digested with HindIII and PstI.
酶切反应体系如下:10μL 10×FastDigest buffer、10μL载体(100ng/μL)、5μLHindIII和5μL PstI,ddH2O 70μL混合后于37℃水浴60min,酶切产物回收线性化载体。The digestion reaction system was as follows: 10 μL of 10×FastDigest buffer, 10 μL of vector (100 ng/μL), 5 μL of HindIII and 5 μL of PstI, 70 μL of ddH 2 O were mixed in a water bath at 37°C for 60 min, and the linearized vector was recovered from the digestion product.
2)以Bacillus HIL Y-8554728基因组为模板,分别用G1/G2、G3/G4和G5/G6为引物扩增mrsK2R2FGE、mrsAR1D和mrsMT基因片段。引物G1和G6与载体存在同源序列,G2与G3,G4与G5也存在同源序列(如图1所示,相同颜色的的区域为同源序列)。2) Taking the genome of Bacillus HIL Y-8554728 as the template, and using G1/G2, G3/G4 and G5/G6 as primers to amplify the mrsK2R2FGE, mrsAR1D and mrsMT gene fragments respectively. Primers G1 and G6 have homologous sequences with the vector, G2 and G3, and G4 and G5 also have homologous sequences (as shown in Figure 1, the regions with the same color are homologous sequences).
扩增体系为50μL:2.5U/μL高保真酶,1μL;2×反应缓冲液,25μL;引物,各1μL;模板,1μL;ddH2O,21μL;扩增条件为:变性,98℃,0.5min;退火55℃,0.5min;延伸68℃,片段1延伸1.5min,片段2延伸3min,片段3延伸2min。The amplification system was 50 μL: 2.5U/μL high-fidelity enzyme, 1 μL; 2× reaction buffer, 25 μL; primers, 1 μL each; template, 1 μL; ddH 2 O, 21 μL; amplification conditions: denaturation, 98°C, 0.5 min; annealing at 55°C for 0.5min; extension at 68°C,
3)将以上三个片段与线性化pP43NMK载体混合后采用重组克隆试剂盒的方法进行连接。3) The above three fragments are mixed with the linearized pP43NMK vector and ligated by the method of recombinant cloning kit.
反应体系如下:5μL 2×Gibson混合液、1μL线性化载体(50ng/μL)、0.9μL回收纯化的DNA片段1(50ng/μL)、1.8μL回收纯化的DNA片段2(50ng/μL)、1.3μL回收纯化的DNA片段3(50ng/μL),混合后于25℃水浴30min,0℃冰浴15min,反应产物转入到大肠杆菌感受态DH5α中,筛选阳性重组子(卡那霉素抗性),即构建成载体pP43NMK-mersacidin(图1)。The reaction system is as follows: 5 μL of 2×Gibson mixture, 1 μL of linearized vector (50 ng/μL), 0.9 μL of recovered and purified DNA fragment 1 (50 ng/μL), 1.8 μL of recovered and purified DNA fragment 2 (50 ng/μL), 1.3 The purified DNA fragment 3 (50ng/μL) was recovered by μL, mixed in a water bath at 25°C for 30 minutes, and an ice bath at 0°C for 15 minutes. The reaction product was transferred into E. coli competent DH5α, and positive recombinants (kanamycin resistance) were screened. ), which was constructed into the vector pP43NMK-mersacidin (Fig. 1).
表达盒基因序列共计12324bp:1到1440为基因mrsK2;1437到2159基因mrsR2;2402到3313基因mrsF;3310到4068基因mrsG;4085到4819基因mrsE;5104到5310基因mrsA;5406到6047基因mrsR1;6096到6680基因mrsD;6892到10080基因mrsM;10132到12324基因mrsT。The gene sequence of the expression cassette is 12324bp in total: 1 to 1440 is the gene mrsK2; 1437 to 2159 is the gene mrsR2; 2402 to 3313 is the mrsF; 3310 to 4068 is the mrsG; 4085 to 4819 is the mrsE; 6096 to 6680 genes mrsD; 6892 to 10080 genes mrsM; 10132 to 12324 genes mrsT.
此载体包括但不仅限于pP43NMK,其他的带有启动子和信号肽的芽孢杆菌表达载体,也可以构建含有Mersacidin表达盒“启动子-mersacidin”的载体。This vector includes but is not limited to pP43NMK, other Bacillus expression vectors with promoter and signal peptide, and a vector containing the Mersacidin expression cassette "promoter-mersacidin" can also be constructed.
实施例2.重组载体的转化Example 2. Transformation of recombinant vectors
将载体pP43NMK-mersacidin通过电转化的方式转入Bacillus subtilis SCK168,电转条件如下:C=50μF;PC=200ohm;V=1.0kV。筛选阳性重组子,命名为MRS08和MRS24。The vector pP43NMK-mersacidin was transferred into Bacillus subtilis SCK168 by electroporation, and the electrotransfer conditions were as follows: C=50μF; PC=200ohm; V=1.0kV. The positive recombinants were screened and named as MRS08 and MRS24.
此宿主菌包括但不仅限于Bacillus subtilis,其他的基因工程菌地衣芽孢杆菌、短小芽孢杆菌,也可以实现载体的转化与表达。The host bacteria include but are not limited to Bacillus subtilis, other genetically engineered bacteria Bacillus licheniformis, Bacillus pumilus, and the transformation and expression of the vector can also be achieved.
实施例3.发酵上清液对金黄色葡萄球菌的抑菌活性的检测Embodiment 3. Detection of the antibacterial activity of fermentation supernatant to Staphylococcus aureus
将筛选得到的MRS08和MRS24菌株在培养基(豆粕粉10g/L,酵母粉10g/L,蛋白胨10g/L,葡萄糖10g/L,氯化钠5g/L)37℃、200rpm/min的条件下培养16-22小时后,不同时间段测定发酵上清液对产气荚膜梭菌的抑菌活性。The MRS08 and MRS24 strains obtained by screening were placed in the culture medium (soybean meal powder 10g/L, yeast powder 10g/L, peptone 10g/L, glucose 10g/L, sodium chloride 5g/L) under the conditions of 37°C and 200rpm/min After culturing for 16-22 hours, the antibacterial activity of the fermentation supernatant against Clostridium perfringens was determined at different time periods.
抑菌活性测定其方法如下:The method for determining the antibacterial activity is as follows:
1)细菌复苏:产气荚膜梭菌ATCC13124平板划线,37℃培养20h;挑取单菌落于相应的液体培养基,置37℃,200rpm/min培养12-16h左右。用生理盐水将菌液稀释至OD600吸光值为0.1(约108CFU/mL),备用;1) Bacterial recovery: Clostridium perfringens ATCC13124 was streaked on the plate and cultured at 37°C for 20h; single colonies were picked and placed in the corresponding liquid medium, and cultured at 37°C and 200rpm/min for about 12-16h. Dilute the bacterial solution with physiological saline to an OD 600 absorbance value of 0.1 (about 10 8 CFU/mL), for subsequent use;
2)取10mL发酵液样品8000g,4℃离心,收集上清-20℃保存待用;2) Take 8000g of 10mL fermentation broth sample, centrifuge at 4°C, collect the supernatant and store it at -20°C for later use;
3)于超净工作台内,吸取100μL指示菌菌液加入到100mL恒温至50±5℃的相应的琼脂培养基中,轻轻摇匀,避免起泡,此时菌在培养基中的含量为106CFU/mL;向每个陪养皿中倒15-20mL,均匀铺平,待其冷却凝固。用无菌打孔器均匀打孔,吸取150-200μL发酵液样品注入到相应的孔内,设立Bacillus subtilis SCK168发酵液为阴性对照,万古霉素(1μg/mL)为阳性对照,同时在培养皿上做好标记,将培养皿放入2-8℃冰箱内放置1-2h进行样品的扩散。将培养皿移入37℃培养箱培养。3) In the ultra-clean workbench, draw 100 μL of the indicator bacteria solution and add it to 100 mL of the corresponding agar medium at a constant temperature of 50±5 °C, shake gently to avoid foaming, and the content of bacteria in the medium at this time. 10 6 CFU/mL; pour 15-20 mL into each petri dish, spread evenly, and wait for it to cool and solidify. Punch holes evenly with a sterile hole punch, draw 150-200 μL of fermentation broth samples and inject them into the corresponding wells. Set up Bacillus subtilis SCK168 fermentation broth as a negative control and vancomycin (1 μg/mL) as a positive control. Make a mark on it, and put the petri dish in a refrigerator at 2-8°C for 1-2h to diffuse the sample. Transfer the petri dish to a 37°C incubator.
在接下来的6-12h内观察菌体的生长情况及抑菌效果,一般8-12h即可观察到抑菌圈,Bacillus subtilis MRS08(图2B)和Bacillus subtilis MRS24(图2C)菌株发酵液的抑菌圈直径与万古霉素(图2D)相当,抑菌效果强。In the next 6-12h, observe the growth of the bacteria and the bacteriostatic effect. Generally, the bacteriostatic zone can be observed in 8-12h. The diameter of the inhibition zone was comparable to that of vancomycin (Fig. 2D), and the bacteriostatic effect was strong.
实施例4.发酵液中Mersacidin的稳定性测定Example 4. Stability determination of Mersacidin in fermentation broth
1)分别取5mL发酵液上清,用5mol/L HCl或5mol/L NaOH调上清液pH值至2.0、7.3和12.0,37℃水浴3小时;1) Take 5 mL of the supernatant of the fermentation broth respectively, adjust the pH of the supernatant to 2.0, 7.3 and 12.0 with 5 mol/L HCl or 5 mol/L NaOH, and take a water bath at 37°C for 3 hours;
2)取5mL发酵液上清,100℃处理1小时;分别向1.5mL的pH调至7.3的发酵上清液加0.2mL胰蛋白酶和蛋白酶K溶液,使酶的终浓度为l mg/mL,37℃水浴4小时,对照组及所有酶的反应体系沸水浴处理5min使酶灭活;2) Take 5 mL of the fermentation broth supernatant and treat at 100°C for 1 hour; add 0.2 mL of trypsin and proteinase K solutions to 1.5 mL of the fermentation supernatant whose pH is adjusted to 7.3, so that the final concentration of the enzyme is 1 mg/mL, The control group and all enzyme reaction systems were treated in a boiling water bath for 5 minutes to inactivate the enzymes;
3)按照实施例3试验步骤检测处理后的发酵液对产气荚膜梭菌的抑菌活性;发现Mersacidin耐酸碱、胰酶和蛋白酶K,高温耐受能力不持久(表2)。3) The bacteriostatic activity of the treated fermentation broth against Clostridium perfringens was detected according to the test procedure of Example 3; it was found that Mersacidin was resistant to acid and alkali, trypsin and proteinase K, and the high temperature tolerance was not durable (Table 2).
表2发酵液对产气荚膜梭菌的抑菌活性的稳定性The stability of the bacteriostatic activity of table 2 fermentation broth to Clostridium perfringens
O:蒸馏水1.25倍稀释5000rpm/min离心10min的离心上清液;O: the centrifugation supernatant diluted 1.25 times with distilled water and centrifuged at 5000rpm/min for 10min;
A:蒸馏水1.25倍稀释离心上清液,pH调至7.3;A: Dilute the centrifugation supernatant 1.25 times with distilled water, and adjust the pH to 7.3;
T:蒸馏水1.25倍稀释离心上清液,pH调至7.3后80℃加热2h;T: Dilute the centrifugation supernatant 1.25 times with distilled water, adjust the pH to 7.3, and heat at 80°C for 2h;
2:胃蛋白酶空白对照;2: pepsin blank control;
7.3:胰蛋白酶、蛋白酶K、过氧化氢酶的空白对照;7.3: Blank control of trypsin, proteinase K, catalase;
P:胃蛋白酶处理;P: pepsin treatment;
Tr:胰蛋白酶处理;Tr: trypsin treatment;
K:蛋白酶K处理;K: proteinase K treatment;
H:过氧化氢酶处理。H: Catalase treatment.
实施例5.发酵液中Mersacidin的含量测定Example 5. Determination of the content of Mersacidin in fermentation broth
将筛选得到的MRS08和MRS24菌株在培养基(豆粕粉10g/L,酵母粉10g/L,蛋白胨10g/L,葡萄糖10g/L,氯化钠5g/L)37℃、200rpm/min的条件下培养,不同时间段测定发酵上清液中Mersacidin的含量;其方法如下:The MRS08 and MRS24 strains obtained by screening were placed in the culture medium (soybean meal powder 10g/L, yeast powder 10g/L, peptone 10g/L, glucose 10g/L, sodium chloride 5g/L) under the conditions of 37°C and 200rpm/min Culture, and measure the content of Mersacidin in the fermentation supernatant at different time periods; the method is as follows:
以生物公司合成的Mersacidin(南京金斯瑞)纯品(含量为99%)为标准,采用高效液相色谱法进行检测,色谱条件如下:Taking the pure Mersacidin (Nanjing GenScript) synthesized by Bio-Company as the standard (content is 99%), it was detected by high performance liquid chromatography. The chromatographic conditions are as follows:
反相色谱柱:C18(4.6×250mm或150mm);Reversed-phase column: C18 (4.6×250mm or 150mm);
洗脱液:流动相A(0.1%三氟乙酸)、流动相B(90%乙腈);Eluent: mobile phase A (0.1% trifluoroacetic acid), mobile phase B (90% acetonitrile);
柱温:25℃(或室温);Column temperature: 25°C (or room temperature);
检测波长:260nm;Detection wavelength: 260nm;
最大压力:200bar;Maximum pressure: 200bar;
按表3进行梯度洗脱:Carry out gradient elution according to Table 3:
表3流动相梯度洗脱程序Table 3 Mobile phase gradient elution procedure
采用此检测方法,其有效成分的最高含量为1.26g/L。Using this detection method, the maximum content of its active ingredients is 1.26g/L.
纯品溶于水中,上样测定纯品的出峰时间,然后发酵液上样。The pure product was dissolved in water, and the sample was loaded to measure the peak time of the pure product, and then the fermentation broth was loaded.
外标法以峰面积和浓度(上样量一致)成正比计算,采用下列公式计算含量:The external standard method is calculated in proportion to the peak area and concentration (consistent sample loading), and the following formula is used to calculate the content:
式中AX为发酵液Mersacidin的峰面积;CX为发酵液中Mersacidin的含量(μg/g);AR为对照品的峰面积:CR为对照品的浓度(μg/mL)。纯品和发酵液图谱为分别为图3A和3B。where AX is the peak area of Mersacidin in the fermentation broth; CX is the content of Mersacidin in the fermentation broth (μg/g); AR is the peak area of the reference substance; CR is the concentration of the reference substance (μg/mL). The pure and fermentation broth profiles are shown in Figures 3A and 3B, respectively.
序列表sequence listing
<110> 重庆市畜牧科学院<110> Chongqing Academy of Animal Husbandry
<120> 用于编码分泌型Mersacidin的基因表达盒及其制备方法<120> Gene expression cassette for encoding secreted Mersacidin and preparation method thereof
<130> 2022.1.14<130> 2022.1.14
<141> 2022-02-24<141> 2022-02-24
<160> 7<160> 7
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 12324<211> 12324
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 1<400> 1
ctaattgaca ttgttatact tagatggcgg actcggaaag gtaattttaa atcttgtgcc 60ctaattgaca ttgttatact tagatggcgg actcggaaag gtaattttaa atcttgtgcc 60
aattcccggc tgactatata tatcaatatt tcccccatgt gccttgataa tttgttgagc 120aattcccggc tgactatata tatcaatatt tcccccatgt gccttgataa tttgttgagc 120
aatagccatt cctaatccag tccctgagtt atttgacgta gcgcttgtcc ctctgaaata 180aatagccatt cctaatccag tccctgagtt atttgacgta gcgcttgtcc ctctgaaata 180
ccgatcaaat aaacattcga ccgtctcttc gtccattcct atcccatcgt cttctattat 240ccgatcaaat aaacattcga ccgtctcttc gtccattcct atcccatcgt cttctattat 240
aatttgtatt tcattgtcat gtaacacgtc ctgatataat atgaccttta ttttagtgcc 300aatttgtatt tcattgtcat gtaacacgtc ctgatataat atgaccttta ttttagtgcc 300
cggaggatta tgtttaatac aattagcaat caagttttca actgcacgct ttaggtacct 360cggaggatta tgtttaatac aattagcaat caagttttca actgcacgct ttaggtacct 360
ttcatccata ttaaaaagta tcttattgtg actggattct aaagcgaatc tcttattttc 420ttcatccata ttaaaaagta tcttattgtg actggattct aaagcgaatc tcttattttc 420
tgactccggt agcagcttca ttttttctaa agtgtcatga attactttca ctacgttttt 480tgactccggt agcagcttca ttttttctaa agtgtcatga attactttca ctacgttttt 480
ttcttcaaga tggattggaa gcgactcatt tttcaattga aaagttaagt tgaaatcttc 540ttcttcaaga tggattggaa gcgactcatt tttcaattga aaagttaagt tgaaatcttc 540
aatcagcttt tccatatatt cgacacgttc ttccattatt aaggaaaaat cacgcacttg 600aatcagcttt tccatatatt cgacacgttc ttccattatt aaggaaaaat cacgcacttg 600
ctgattttcc cactcatatt catttgaaga taaaagaacc gtatatccct taataaccga 660ctgattttcc cactcatatt catttgaaga taaaagaacc gtatatccct taataaccga 660
aagaggggtt tttaaatcat gtgagacacc ggccatccac tcttctcgtg tcttttccaa 720aagaggggtt tttaaatcat gtgagacacc ggccatccac tcttctcgtg tcttttccaa 720
taattctcgc tcagccttat tcctttgaag cgttgaggta agttcagaca gagcctgcat 780taattctcgc tcagccttat tcctttgaag cgttgaggta agttcagaca gagcctgcat 780
taattcttga taggtcttat atccagattt attatgtcta tatttgcttg aatgaaactt 840taattcttga taggtcttat atccagattt attatgtcta tatttgcttg aatgaaactt 840
ccaatcataa ggttcttcat atttttcttt agacaaattc tcaatccaag atacaataaa 900ccaatcataa ggttcttcat atttttcttt agacaaattc tcaatccaag atacaataaa 900
cagcagggga gcacctagtt tttttccgta aaatattgca atgacaatcc ctgccataat 960cagcagggga gcacctagtt tttttccgta aaatattgca atgacaatcc ctgccataat 960
aatagaaaca atccacaagt tattcaccca atagaaaaaa gggttatttt tttccatcgg 1020aatagaaaca atccacaagt tattcaccca atagaaaaaa gggttatttt tttccatcgg 1020
ctttcccaat acccatgtta aatcctgatt gtttttcgtt tcataccacg tagataattg 1080ctttcccaat acccatgtta aatcctgatt gtttttcgtt tcataccacg tagataattg 1080
ataacctttt ttggcaggat acatgtaatc tgatattaac tctccaagaa tataatgctt 1140ataacctttt ttggcaggat acatgtaatc tgatattaac tctccaagaa tataatgctt 1140
aggtatattt tgaggtttat taaaagaaaa aacctcatct ccttgttcat ctaaaatttg 1200aggtatattt tgaggtttat taaaagaaaa aacctcatct ccttgttcat ctaaaatttg 1200
aatccacatc cggttctcta ataaatcttc ttttgctttc gtatttattg aaaattgttt 1260aatccacatc cggttctcta ataaatcttc ttttgctttc gtatttattg aaaattgttt 1260
atctgcaaca actgtttggt caacaatttt ttttaaggat aagtgcggcg tttccatttt 1320atctgcaaca actgtttggt caacaatttt ttttaaggat aagtgcggcg tttccatttt 1320
attctgacct aagacgaggc tgaaaaatat gatactgccc acaatgagca caccccaaat 1380attctgacct aagacgaggc tgaaaaatat gatactgccc acaatgagca caccccaaat 1380
aaacatgagt aaaaaaagtc tcgatacgaa gtaaaatgct atcctatttc tcagcttcaa 1440aaacatgagt aaaaaaagtc tcgatacgaa gtaaaatgct atcctatttc tcagcttcaa 1440
aataaatcct catctatagg ctctgcttca aatatatagc cctgtcctcg aaccgtttta 1500aataaatcct catctatagg ctctgcttca aatatatagc cctgtcctcg aaccgtttta 1500
atccatctag gtctgctcgg gtcttcctct aatttttcac gtaatcgtct tacatgtacc 1560atccatctag gtctgctcgg gtcttcctct aatttttcac gtaatcgtct tacatgtacc 1560
attacagtac tatctccgcc ataaaactcc ccccacacat ctttataaat ttggtgttta 1620attacagtac tatctccgcc ataaaactcc ccccacacat ctttataaat ttggtgttta 1620
cttaaaattt gattgggatg ttcacagaaa taaatcagaa gtttcatttc ctgagcaggg 1680cttaaaattt gattgggatg ttcacagaaa taaatcagaa gtttcatttc ctgagcaggg 1680
caatctattc ttgtcccgtt aacaacaagt cttccggtat tgggatctat tttaaaatat 1740caatctattc ttgtcccgtt aacaacaagt cttccggtat tgggatctat tttaaaatat 1740
tcataatcgt atacctgttt tagagggtaa gaagaagaga gttgagtcgt tctctttaat 1800tcataatcgt atacctgttt tagagggtaa gaagaagaga gttgagtcgt tctctttaat 1800
tgggctttta cacgagctac aatttctagt ggattaaatg gtttagtaat atagtcatct 1860tgggctttta cacgagctac aatttctagt ggattaaatg gtttagtaat atagtcatct 1860
cccccaaaac taaacccttg caatttatct aaatctgttg tttttgccgt taagaagagt 1920cccccaaaac taaacccttg caatttatct aaatctgttg ttttttgccgt taagaagagt 1920
atcggcacat ttgtatgcga gcgtattttg ctgcataagg tgaagccatc agtgtccgga 1980atcggcacat ttgtatgcga gcgtattttg ctgcataagg tgaagccatc agtgtccgga 1980
agcatgacat ctaataaaat aatatttgga agttcctgat cgattttcag aagggtttcg 2040agcatgacat ctaataaaat aatatttgga agttcctgat cgattttcag aagggtttcg 2040
ctccctgtca tagctgtgga aatattgctg aaaccttcct tttcaaagca agttattaat 2100ctccctgtca tagctgtgga aatattgctg aaaccttcct tttcaaagca agttattaat 2100
aagtttaaga tatgttcgtc atcatccacc atgaggattt tgttctcttc taacgtcata 2160aagtttaaga tatgttcgtc atcatccacc atgaggattt tgttctcttc taacgtcata 2160
agttaccctc ctttttattt cttattttat atgagatcaa tgacataaag gtcagaaaag 2220agttaccctc ctttttattt cttattttat atgagatcaa tgacataaag gtcagaaaag 2220
gaaagaattt aactttcgtt aagggttcag aatattcttt cgaattttta accttgatat 2280gaaagaattt aactttcgtt aagggttcag aatattcttt cgaattttta accttgatat 2280
tcaggtatca atataactac atacagaaaa taaaccaggg atgtcgttaa gtgaatgttt 2340tcaggtatca atataactac atacagaaaa taaaccaggg atgtcgttaa gtgaatgttt 2340
aggaagagtt tcgtttgtgt ttaaagaaca tcgcttatga taaaagtgag gtgagagaca 2400aggaagagtt tcgtttgtgt ttaaagaaca tcgcttatga taaaagtgag gtgagagaca 2400
aatgaatgat caaatagtgg taacacacga tctgactaaa aagtataaaa agcatacttc 2460aatgaatgat caaatagtgg taacacacga tctgactaaa aagtataaaa agcatacttc 2460
tgttgatgga ttaaacttaa ggattaggcg tggcgaaatt tatggttttc ttggaccgaa 2520tgttgatgga ttaaacttaa ggattaggcg tggcgaaatt tatggttttc ttggaccgaa 2520
tggtgctggt aaaacaacaa ccatccgaat gttattaggt ttaattaaac caacaaaagg 2580tggtgctggt aaaacaacaa ccatccgaat gttattaggt ttaattaaac caacaaaagg 2580
aaacatcgaa atctttggcc aaaacctaaa caagaatcgt ttgcagatat tgcaaagaat 2640aaacatcgaa atctttggcc aaaacctaaa caagaatcgt ttgcagatat tgcaaagaat 2640
cgggtcactg gtagaatctc caacttatta tggtaattta acaggttacg aaaacttaga 2700cgggtcactg gtagaatctc caacttatta tggtaattta acaggttacg aaaacttaga 2700
agctgttagg aggttacgag gacttccgga acaacaggtc aatgaagtat tggaaactgt 2760agctgttagg aggttacgag gacttccgga acaacaggtc aatgaagtat tggaaactgt 2760
aaggttatct aaagtagcaa atcgactgac taaggagtat tcccttggaa tgaaacaacg 2820aaggttatct aaagtagcaa atcgactgac taaggagtat tcccttggaa tgaaacaacg 2820
tttgggaatt gcagttgccc tgttaagcag tcctgattta ttaattctgg atgaaccgac 2880tttgggaatt gcagttgccc tgttaagcag tcctgattta ttaattctgg atgaaccgac 2880
aaatggttta gatccatccg gtatccaaga aataagagag ctaattaaag aattgcctaa 2940aaatggttta gatccatccg gtatccaaga aataagagag ctaattaaag aattgcctaa 2940
atcgggaatg agtgttattg tatccagcca cttattgagt gaaatagatc aaatggctac 3000atcgggaatg agtgttattg tatccagcca cttattgagt gaaatagatc aaatggctac 3000
tcaagtggga attatcaaca atggaaaaat gatttttcag gactcgattg caagtttaca 3060tcaagtggga attatcaaca atggaaaaat gatttttcag gactcgattg caagtttaca 3060
tcaaaaaaga aaaccactat taaaagtcgg tgttagtgac gtaatcgaag caaaaacaat 3120tcaaaaaaga aaaccactat taaaagtcgg tgttagtgac gtaatcgaag caaaaacaat 3120
attaaacagg aaaggattaa aggttgattt acaaaaaaat tatttgtggc tgtctcaaac 3180attaaacagg aaaggattaa aggttgattt acaaaaaaat tatttgtggc tgtctcaaac 3180
agaaccggaa ttcgtttcag aaatcaattc catacttctt cattcagggc tgtctgtatt 3240agaaccggaa ttcgtttcag aaatcaattc catacttctt cattcagggc tgtctgtatt 3240
tcgacttgaa gaaaagacac gatcacttga ggatattttt ttagaattaa ccggtacaga 3300tcgacttgaa gaaaagacac gatcacttga ggatattttt ttagaattaa ccggtacaga 3300
gggaagtcta tgaaaaagtt attatgggca gatcaattaa aactgaaacg ttcgtcgtta 3360gggaagtcta tgaaaaagtt attatgggca gatcaattaa aactgaaacg ttcgtcgtta 3360
ttgattgtag tcttattggt tcccttactc attatagcat atgagttggt aaatcttact 3420ttgattgtag tcttattggt tcccttactc attatagcat atgagttggt aaatcttact 3420
tatcgatctg aatacgtgga aaaacaagct gaaatgttcc atgctggatc aatgtggatg 3480tatcgatctg aatacgtgga aaaacaagct gaaatgttcc atgctggatc aatgtggatg 3480
tatttactgt atgataacag tttgttattt ggtctgggtt ttccattagc cgccacactt 3540tatttactgt atgataacag tttgttattt ggtctgggtt ttccattagc cgccacactt 3540
tctgcgtcaa taatagcaaa tatagagcat caagcaaacg gatggaagca aaccctttct 3600tctgcgtcaa taatagcaaa tatagagcat caagcaaacg gatggaagca aaccctttct 3600
tttcctgtat ctagaatgcg aatttatgta agtaaattta tttgcttagt agtcagttta 3660tttcctgtat ctagaatgcg aatttatgta agtaaattta tttgcttagt agtcagttta 3660
tttatttcgt caacaatctt cttgctcggc atggtactgc tgggcaaact ggtaggattc 3720tttatttcgt caacaatctt cttgctcggc atggtactgc tgggcaaact ggtaggattc 3720
gaaggtagtg taccttgggg acttttgttt ggagatagtt acagcatgtt agttacagta 3780gaaggtagtg taccttgggg acttttgttt ggagatagtt acagcatgtt agttacagta 3780
ctgcctataa tggcattcca gatatggtta tctatggtgt ttagcaacca agcattctca 3840ctgcctataa tggcattcca gatatggtta tctatggtgt ttagcaacca agcattctca 3840
attcttgtag gatcagtatc atctataatg ggtttgtttt tggcagctgc tcaatcaacg 3900attcttgtag gatcagtatc atctataatg ggtttgtttt tggcagctgc tcaatcaacg 3900
agatggtttc cgctggctta tcctagtcaa tcttcgacag tcattctgca gtatgaaggt 3960agatggtttc cgctggctta tcctagtcaa tcttcgacag tcattctgca gtatgaaggt 3960
ataggatata acccagatct ttcatcttac ctttgcatta gccttttctt agggataatt 4020ataggatata acccagatct ttcatcttac ctttgcatta gccttttctt agggataatt 4020
atattatttc taggctctat tcattttgct aaacgggatg ctttgtaaaa aggaggcgaa 4080atattatttc taggctctat tcattttgct aaacgggatg ctttgtaaaa aggaggcgaa 4080
atacttgaaa aacattttat ttgtagaacg tttaaagctt aagcgatcaa agttatggat 4140atacttgaaa aacattttat ttgtagaacg tttaaagctt aagcgatcaa agttatggat 4140
catctactta ttagggcctt tgttaggtgt atccctggca tacactaact ttattaaaaa 4200catctactta ttagggcctt tgttaggtgt atccctggca tacactaact ttattaaaaa 4200
ctataacctt tttatgaatc ccggagacaa tccctgggta gaggcttgga cacaagttgc 4260ctataacctt tttatgaatc ccggagacaa tccctgggta gaggcttgga cacaagttgc 4260
cttatttatg ggcccttttg tattgcctat cgtagtggga attttcgccg cccttgtttg 4320cttatttatg ggcccttttg tattgcctat cgtagtggga attttcgccg cccttgtttg 4320
caggggggaa catgtaggag gcggttggaa acagcttcta gccttaccag tcaaacactc 4380cagggggggaa catgtaggag gcggttggaa acagcttcta gccttaccag tcaaacactc 4380
agatatcttt ctgggaaagt ttctaacagt ggtccgcatg atattcatta gtatgtccat 4440agatatcttt ctgggaaagt ttctaacagt ggtccgcatg atattcatta gtatgtccat 4440
tttaatcctc ttatttattg gattcggtta tatgttaggc ataagcggga gtcttccttt 4500tttaatcctc ttatttattg gattcggtta tatgtttaggc ataagcggga gtcttccttt 4500
acttacaatt ctaggttatg gaattagagg gatcttagct tgtttaccat taattttatt 4560acttacaatt ctaggttatg gaattagagg gatcttagct tgtttaccat taattttatt 4560
gcagcttatt gtttcaatca ggtctaaaac atttggcata ccactcgctg ttagcattgt 4620gcagcttatt gtttcaatca ggtctaaaac atttggcata ccactcgctg ttagcattgt 4620
ttttacatta ccggccatta ttattgccag tacaccatta ggtcaagtat atccatggac 4680ttttacatta ccggccatta ttattgccag tacaccatta ggtcaagtat atccatggac 4680
acagcctatg ttagcaatgt cacccgaaga tgaatcaccg attcaatcaa atttcctgtt 4740acagcctatg ttagcaatgt cacccgaaga tgaatcaccg attcaatcaa atttcctgtt 4740
ttactcaatt atggtaataa cgtgtctcgg tctcctggtt tacggaataa gaagttttac 4800ttactcaatt atggtaataa cgtgtctcgg tctcctggtt tacggaataa gaagttttac 4800
taaacgagac cttacgtagg gtatatgcgg tataaactta tgagaattcg agacaaggta 4860taaacgagac cttacgtagg gtatatgcgg tataaactta tgagaattcg agacaaggta 4860
aactaatttg actagcgcta tgtaaaacag aaatttatat gaaggtaaga ctaaatcttt 4920aactaatttg actagcgcta tgtaaaacag aaatttatat gaaggtaaga ctaaatcttt 4920
ttggttgtat tctttgaaac taaacgacta atggaaaagg tgatgtttca aagcataaga 4980ttggttgtat tctttgaaac taaacgacta atggaaaagg tgatgtttca aagcataaga 4980
cataagaaat ataaagatat cttaagactc tttatttaaa cattttttac atttaataat 5040cataagaaat ataaagatat cttaagactc tttatttaaa cattttttac atttaataat 5040
atctcttcca tttttttgat tatgagttaa tataatacta tacttaataa gggggtgaat 5100atctcttcca ttttttttgat tatgagttaa tataatacta tacttaataa gggggtgaat 5100
acaatgagtc aagaagctat cattcgttca tggaaagatc ctttttcccg tgaaaattct 5160acaatgagtc aagaagctat cattcgttca tggaaagatc ctttttcccg tgaaaattct 5160
acacaaaatc cagctggtaa cccattcagt gagctgaaag aagcacaaat ggataagtta 5220acacaaaatc cagctggtaa cccattcagt gagctgaaag aagcacaaat ggataagtta 5220
gtaggtgcgg gagacatgga agcagcatgt acttttacat tgcctggtgg cggcggtgtt 5280gtaggtgcgg gagacatgga agcagcatgt acttttacat tgcctggtgg cggcggtgtt 5280
tgtactctaa cttctgaatg tatttgttaa tttgatttat ataggctgtt tcccttcaga 5340tgtactctaa cttctgaatg tatttgttaa tttgatttat ataggctgtt tcccttcaga 5340
aggaacagcc tatattttat tatataaact attagaaaat tcttaaaaaa caggagggta 5400aggaacagcc tatattttat tatataaact attagaaaat tcttaaaaaa caggagggta 5400
aatcattggg gaaaactctc gtttgttcag aaaatagcta tttccaagca tatatgaatc 5460aatcattggg gaaaactctc gtttgttcag aaaatagcta tttccaagca tatatgaatc 5460
atttattaac gccagatagt aatgaaataa taaatgttaa cacattggat gaactaaaac 5520atttattaac gccagatagt aatgaaataa taaatgttaa cacattggat gaactaaaac 5520
aaataatatc caaagaaaat ttttcctctg taatcatcga tacttgccac cctaatgact 5580aaataatatc caaagaaaat ttttcctctg taatcatcga tacttgccac cctaatgact 5580
tagtgttgca actgataaaa tcgatatctt gcccagtcat aatacttaac tccttagaaa 5640tagtgttgca actgataaaa tcgatatctt gcccagtcat aatacttaac tccttagaaa 5640
ctaacgtttc agattataac cctggtccaa tattaaatca aataaataat gtttcaaccc 5700ctaacgtttc agattataac cctggtccaa tattaaatca aataaataat gtttcaaccc 5700
taaaacataa tgtttttcaa ttgtctttca caactttttt cgacgttgga aagcattgta 5760taaaacataa tgtttttcaa ttgtctttca caactttttt cgacgttgga aagcattgta 5760
tttggaaaaa gaatgaatat atccctctag caatacaaga atttaaaatt ttatatttgc 5820tttggaaaaa gaatgaatat atccctctag caatacaaga atttaaaatt ttatatttgc 5820
tttatttaaa ttcaaataaa atagtctgtt ctgaagaact tattgaatat gctgacctta 5880tttatttaaa ttcaaataaa atagtctgtt ctgaagaact tattgaatat gctgacctta 5880
ctggtaggtc aagtctttat gtacacatta gttctcttag agaaaaagta gaggataacc 5940ctggtaggtc aagtctttat gtacacatta gttctcttag agaaaaagta gaggataacc 5940
ctggagatcc aaagattctt caaacaaagt ttggaaaagg gtacctctta tctgacagta 6000ctggagatcc aaagattctt caaacaaagt ttggaaaagg gtacctctta tctgacagta 6000
catatatttg tcttgaaaaa aaagcagact caaaaaatgt cgtgtaaaaa ggatgaccca 6060catatatttg tcttgaaaaa aaagcagact caaaaaatgt cgtgtaaaaa ggatgaccca 6060
aaaatcattt taaaatgact tttgagtcat cccatttatg ttagtgaggg gtgttttgtt 6120aaaatcattt taaaatgact tttgagtcat cccatttatg ttagtgaggg gtgttttgtt 6120
ctttctttaa aacctttttc tattgctaat aaagctttgt cgggtgtaat tagaccacga 6180ctttctttaa aaccttttttc tattgctaat aaagctttgt cgggtgtaat tagaccacga 6180
ttaggttttc ttgtacccgt cgcaatctca aacgccataa tttcaactgg ttcaataaca 6240ttaggttttc ttgtacccgt cgcaatctca aacgccataa tttcaactgg ttcaataaca 6240
atatgcccat cttttcttaa ttgttcaata ttcctggaaa caactgtttt attccacatt 6300atatgcccat cttttcttaa ttgttcaata ttcctggaaa caactgtttt attccacatt 6300
aaatcgttca tattaggaaa gaaaatagtg ttatgtggat gagctaatac agtagttgca 6360aaatcgttca tattaggaaa gaaaatagtg ttatgtggat gagctaatac agtagttgca 6360
actaaattca ttgctacacc attagcagtt tgtcctaaga tgttcgctgt agctggaata 6420actaaattca ttgctacacc attagcagtt tgtcctaaga tgttcgctgt agctggaata 6420
atgcaatata tgtccgccca gcggccaatt tctacgtggc tatgtctttt tccgttttcc 6480atgcaatata tgtccgccca gcggccaatt tctacgtggc tatgtctttt tccgttttcc 6480
ccatgttctg agtatacatg gtcacaaaaa taagaaacag tatgagctgg aataaggtct 6540ccatgttctg agtatacatg gtcacaaaaa taagaaacag tatgagctgg aataaggtct 6540
tccgctgttt ttgtcataac aacccttatt tccttaaaga agcttttaaa atataagaga 6600tccgctgttt ttgtcataac aacccttatt tccttaaaga agcttttaaa atataagaga 6600
tacgaggaga tgccgacaga tgagattgat ccgcaaatcc cgatcaataa ctttttatct 6660tacgaggaga tgccgacaga tgagattgat ccgcaaatcc cgatcaataa ctttttatct 6660
tttaatattg aaatactcat ttttttctcc ctctgtaaat tttaaacaat catactacac 6720tttaatattg aaatactcat ttttttctcc ctctgtaaat tttaaacaat catactacac 6720
aattattctt tttgtggtgt ttattccaaa tattaaatat tcttaataaa cacatataaa 6780aattattctt tttgtggtgt ttattccaaa tattaaatat tcttaataaa cacatataaa 6780
ataaacctaa acttctttta aaattctttt aacttttaaa tggctctgct atatttatgg 6840ataaacctaa acttctttta aaattctttt aacttttaaa tggctctgct atatttatgg 6840
ataattaagg aatattaatt gttcaaattt attaaaaatg aggtgttcaa tatgcataca 6900ataattaagg aatattaatt gttcaaattt attaaaaatg aggtgttcaa tatgcataca 6900
aaattcaaac ggaattcggt atggaatagg tcttcttcga taagtgaaag aaaagtaagg 6960aaattcaaac ggaattcggt atggaatagg tcttcttcga taagtgaaag aaaagtaagg 6960
cgttcactta atactaattg ggatgaacta acaaacagac gcttcgaaag atggaaaagc 7020cgttcactta atactaattg ggatgaacta acaaacagac gcttcgaaag atggaaaagc 7020
cttgttgaaa gtgatgaggg gattcgaatt gaggatgtat tagccaccca aaatattgac 7080cttgttgaaa gtgatgaggg gattcgaatt gaggatgtat tagccaccca aaatattgac 7080
gaagaaaccc taaagcatac tatcaatgca aaagaagtgg aatttattaa tgaaggtgat 7140gaagaaaccc taaagcatac tatcaatgca aaagaagtgg aatttattaa tgaaggtgat 7140
catcaaggat ggcttgaaat tattcagcta gttgatgaac aatcctataa aaatgtaaat 7200catcaaggat ggcttgaaat tattcagcta gttgatgaac aatcctataa aaatgtaaat 7200
atagaagtta gaaaagatat tctcttcttt agttttataa aaccattttt gaaaatagca 7260atagaagtta gaaaagatat tctcttcttt agttttataa aaccattttt gaaaatagca 7260
agaggcaaat tagaggaagt attatattct cactctacta aatctctgat aaaggaagaa 7320agaggcaaat tagaggaagt attattattct cactctacta aatctctgat aaaggaagaa 7320
cttagtccgt cggtaattga tgatttactt aataatcttg gtgaaacttt atcagctata 7380cttagtccgt cggtaattga tgatttactt aataatcttg gtgaaacttt atcagctata 7380
agtagtcgga tattaatatt ggagttaaat gtagcaaggg tatcaggaaa gctgcggggt 7440agtagtcgga tattaatatt ggagttaaat gtagcaaggg tatcaggaaa gctgcggggt 7440
gaaacttctg aagaacgagc ctcttatttc aatcaagccc ttttaaatga cccggcatat 7500gaaacttctg aagaacgagc ctcttatttc aatcaagccc ttttaaatga cccggcatat 7500
gttcgatcaa ttcgagaaga atacatagtt ttaacaaggc tgttagcaac aaaaacaatg 7560gttcgatcaa ttcgagaaga atacatagtt ttaacaaggc tgttagcaac aaaaacaatg 7560
tattggattc aaaatacttc tgatctcctt gtaagatttc atcaggataa agggatatta 7620tattggattc aaaatacttc tgatctcctt gtaagatttc atcaggataa agggatatta 7620
gaatctgagt ttagtaatgg tcaaaaatta gggaaaatta tttccatcga tacaggaagt 7680gaatctgagt ttagtaatgg tcaaaaatta gggaaaatta tttccatcga tacaggaagt 7680
ggcgtctcag atactcataa caaaggaaaa acagtcgcca ttttaaactt tgaaactgga 7740ggcgtctcag atactcataa caaaggaaaa acagtcgcca ttttaaactt tgaaactgga 7740
attaaaattg tgtataagcc tcgttcatta gaaatagacg taaaatttaa taaatttgta 7800attaaaattg tgtataagcc tcgttcatta gaaatagacg taaaatttaa taaatttgta 7800
aattatctaa atggtaaaaa tttaagtttt gacttaaaaa ctgtacacac acttaacaaa 7860aattatctaa atggtaaaaa tttaagtttt gacttaaaaa ctgtacacac acttaacaaa 7860
aaatcttatg gatggacgca gtttatctct tataaagaat gtcaggaaga actgcaaatt 7920aaatcttatg gatggacgca gtttatctct tataaagaat gtcaggaaga actgcaaatt 7920
ggaaagtttt attggcgtat tggaagttat ttggctatct tatatgcaat gaatgcggta 7980ggaaagtttt attggcgtat tggaagttat ttggctatct tatatgcaat gaatgcggta 7980
gattttcata tgcaaaattt aattgctgat ggagaatatc ctattttagt tgatttagaa 8040gattttcata tgcaaaattt aattgctgat ggagaatatc ctattttagt tgatttagaa 8040
tctttatttc ataataattc tacgtataca gataccagtg cttttagtcg cgcacaagaa 8100tctttatttc ataataattc tacgtataca gataccagtg cttttagtcg cgcacaagaa 8100
catattgaac ggtcagtttt acgaattggg ttattaccga gaaaaataaa tagtaaagct 8160catattgaac ggtcagtttt acgaattggg ttattaccga gaaaaataaa tagtaaagct 8160
ggatttgaag gaattgacct tagtgcatta ggtgcacaag aaggacaagt atctccgcat 8220ggatttgaag gaattgacct tagtgcatta ggtgcacaag aaggacaagt atctccgcat 8220
aaaaccagta caatagttga tcgagataaa gatacagtca ggatagaaga aaaaaacttt 8280aaaaccagta caatagttga tcgagataaa gatacagtca ggatagaaga aaaaaacttt 8280
ccaattccag ttagtcagca tagacctatg ctgcatggac aaatcattaa tactgttgct 8340ccaattccag ttagtcagca tagacctatg ctgcatggac aaatcattaa tactgttgct 8340
tacgaaggaa atattataaa aggatttgaa gaaacctact tccttttcat gaaatataaa 8400tacgaaggaa atattataaa aggatttgaa gaaacctact tccttttcat gaaatataaa 8400
caagacatgc tcgaacaaat agattctttt aaaggggtta ctgtaagaca aatattgcgt 8460caagacatgc tcgaacaaat agattctttt aaaggggtta ctgtaagaca aatattgcgt 8460
ggtacatctc gctatgcaaa ccttctgaaa ataagtttac atccagattt catgagagac 8520ggtacatctc gctatgcaaa ccttctgaaa ataagtttac atccagattt catgagagac 8520
ggcttagatc gtgaaatgat tttagataaa ttgtggctag atacaaaatt gaatccacga 8580ggcttagatc gtgaaatgat tttagataaa ttgtggctag atacaaaatt gaatccacga 8580
ttgaaccaag ttgtaaatag tgaaaaggaa ggcttattcc ttggggatat cccatatttc 8640ttgaaccaag ttgtaaatag tgaaaaggaa ggcttattcc ttggggatat cccatatttc 8640
acaagcaagc ctgaatctac aaatatgtgg gattccagcg gtcgaaaaat caacaatttt 8700acaagcaagc ctgaatctac aaatatgtgg gattccagcg gtcgaaaaat caacaatttt 8700
tttaaaacaa gtgccttaaa tgagacaaag gaaaaaataa atgaaatgaa tgaaagtgac 8760tttaaaacaa gtgccttaaa tgagacaaag gaaaaaataa atgaaatgaa tgaaagtgac 8760
tgtcatgaac aagtaagctt tataaaaaca gctattttag taattaagga ttcttatcgt 8820tgtcatgaac aagtaagctt tataaaaaca gctattttag taattaagga ttcttatcgt 8820
aaacataaag tatttgatat aaatcctcga ttacacgttt ttaacccaaa agattttttt 8880aaacataaag tatttgatat aaatcctcga ttacacgttt ttaacccaaa agatttttttt 8880
caagaagcta ttaaaatcgg agactttctt gctagtaggg cgattgaagg tgaacagtta 8940caagaagcta ttaaaatcgg agactttctt gctagtaggg cgattgaagg tgaacagtta 8940
gatggacaag aggatgtatc ttggatcgga tcgtttgttg acaatcaacg agaggatcaa 9000gatggacaag aggatgtatc ttggatcgga tcgtttgttg acaatcaacg agaggatcaa 9000
ttcaagattt cagctgcaaa tagttcatta tacgagggtg taggtggtat ttctctcttc 9060ttcaagattt cagctgcaaa tagttcatta tacgagggtg taggtggtat ttctctcttc 9060
cttgcttatt taggtcgcct ctctaacaat gaaaaataca ccaaactatc taaaaaagct 9120cttgcttatt taggtcgcct ctctaacaat gaaaaataca ccaaactatc taaaaaagct 9120
ttagtggcag tacacaaaaa tatgtctgca tctagtgatt taggtgcctt tgggggaatt 9180ttagtggcag tacacaaaaa tatgtctgca tctagtgatt taggtgcctt tgggggaatt 9180
gcttcttacc tttatttgtt ggatcattta tcaaaattat ggaatgatga acaactattg 9240gcttcttacc ttatttgtt ggatcattta tcaaaattat ggaatgatga acaactattg 9240
aaaaacgaac tttattctgc cctcaacaaa ttagattctt tgatcgaaag ggatgaaaac 9300aaaaacgaac tttattctgc cctcaacaaa ttagattctt tgatcgaaag ggatgaaaac 9300
aacgatattt taacaggggt ggctgggaca gcagttattt taataaattt gtttaaacgg 9360aacgatattt taacaggggt ggctgggaca gcagttattt taataaattt gtttaaacgg 9360
tataaagaag aacaaatctt aaacttgatt acaaaatgcg gaaatcgtct tattcaaaat 9420tataaagaag aacaaatctt aaacttgatt acaaaatgcg gaaatcgtct tattcaaaat 9420
ataaacgtta tggaaaaggg agttggatgg aaagtcccgg caaacccaac gccagcctcc 9480ataaacgtta tggaaaaggg agttggatgg aaagtcccgg caaacccaac gccagcctcc 9480
ggatttgctc atggtgcctc aggaattata tgggctcttt atgagattta cgcaattact 9540ggatttgctc atggtgcctc aggaattata tgggctcttt atgagattta cgcaattact 9540
aagcaaactg tatttaaaga ggtagctgaa aaagcgttag aatttgaaag aactttgttt 9600aagcaaactg tatttaaaga ggtagctgaa aaagcgttag aatttgaaag aactttgttt 9600
attccggaaa aaaacaattg ggcagatatt aaacttgaaa acggacagtt tcgaaatgat 9660attccggaaa aaaacaattg ggcagatatt aaacttgaaa acggacagtt tcgaaatgat 9660
aattttgttg cttggtgtaa tggcgcagca ggcataggat taagtaggat attgatcctg 9720aattttgttg cttggtgtaa tggcgcagca ggcataggat taagtaggat attgatcctg 9720
ccacacaatc aaaatgaatt gataaaagat gaagcacatg tcgcaattaa tacaacccta 9780ccacacaatc aaaatgaatt gataaaagat gaagcacatg tcgcaattaa tacaacccta 9780
aaatatggtt ttgaacatga tcaatcttta tgccatggtg atttaggtaa tctggacatc 9840aaatatggtt ttgaacatga tcaatcttta tgccatggtg atttaggtaa tctggacatc 9840
cttatgtacg cagcggaaaa ctttaataaa aagttaagcg taaatgtaac agaactaagc 9900cttatgtacg cagcggaaaa ctttaataaa aagttaagcg taaatgtaac agaactaagc 9900
cataaaattt taaatgatat aaagctcaga ggatggttaa ctggatttga aaaaaataac 9960cataaaattt taaatgatat aaagctcaga ggatggttaa ctggatttga aaaaaataac 9960
gaatccccat ccttaatgat ggggtatgca ggtataggac ttggattgct taagattttt 10020gaatccccat ccttaatgat ggggtatgca ggtataggac ttggattgct taagattttt 10020
gcaccagtcg aagtgccatc agttttgaga ctccaatcac ctttagaact aaaattgtaa 10080gcaccagtcg aagtgccatc agttttgaga ctccaatcac ctttagaact aaaattgtaa 10080
aattaaaatg agccttactt tgttaaggct ctatttctta gaggtgatcc aatgagaaga 10140aattaaaatg agccttactt tgttaaggct ctatttctta gaggtgatcc aatgagaaga 10140
agagttcctc tagtaaggca aatgggacaa tatgagtgtg ggcccgcctg tctcaccatg 10200agagttcctc tagtaaggca aatgggacaa tatgagtgtg ggcccgcctg tctcaccatg 10200
attttaagtt attatgggag tactatatct ctaaataaaa taagtgaaca atgtgatgcc 10260attttaagtt attatgggag tactatatct ctaaataaaa taagtgaaca atgtgatgcc 10260
caaagaaatg gcgtatctgt atccatttta aaatcagtat cagaatatta tgggcttaac 10320caaagaaatg gcgtatctgt atccatttta aaatcagtat cagaatatta tgggcttaac 10320
tgcaaagtat accaagtttc gtttaaagat ttgaaaaaat atatcaattc atatcttccc 10380tgcaaagtat accaagtttc gtttaaagat ttgaaaaaat atatcaattc atatcttccc 10380
tgcatcatat tttgggatga acggcacttt gtggttttag aacagattaa aaaaggtctt 10440tgcatcatat tttgggatga acggcacttt gtggttttag aacagattaa aaaaggtctt 10440
tttcatataa ttgaccccaa cagaggaaaa ttgaaattat ccgaagaaga atttaaaaga 10500tttcatataa ttgaccccaa cagaggaaaa ttgaaattat ccgaagaaga atttaaaaga 10500
cattatagca aggtaatctt gacttttaag aagtcagata aatttaaaga gatgatgcca 10560cattatagca aggtaatctt gacttttaag aagtcagata aatttaaaga gatgatgcca 10560
tcacccgcag caaagtatta tttacgttat atagttaaaa gccgtactat tgtttcactt 10620tcacccgcag caaagtatta tttacgttat atagttaaaa gccgtactat tgtttcactt 10620
atcattctct tttcactgat cacacaagta gtcttcttag ccgttccttt tttaattaaa 10680atcattctct tttcactgat cacacaagta gtcttcttag ccgttccttt tttaattaaa 10680
tatttagtgg atcattcttt aataagtaaa tcaacaaatt cttttctatt tttaggaatt 10740tatttagtgg atcattcttt aataagtaaa tcaacaaatt cttttctatt tttaggaatt 10740
gtagtcatca tagcagtttt tatattggga cttgttatgt ttatccgcaa ttatttcaca 10800gtagtcatca tagcagttttt tatattggga cttgttatgt ttatccgcaa ttatttcaca 10800
attaaacttc aagctattat aagtaaaagc atctcaaacg attttgtgga acatttatta 10860attaaacttc aagctattat aagtaaaagc atctcaaacg attttgtgga acatttatta 10860
aaattacctc tcaattttta tgaaaatcga acaaccggtg atattgcaat gagagtaagt 10920aaattacctc tcaattttta tgaaaatcga acaaccggtg atattgcaat gagagtaagt 10920
aacatttcca tgataaggga gattatagct aagaatggag caacaatagt actagatatt 10980aacatttcca tgataaggga gattatagct aagaatggag caacaatagt actagatatt 10980
attactttga tttcattttt tattgctatg ttaactcaat catttaaact tgcatttttt 11040attactttga tttcattttt tattgctatg ttaactcaat catttaaact tgcatttttt 11040
gctattggat tggcaattat tcaattctta ctaatgatga ttttgattcc aagaataaaa 11100gctattggat tggcaattat tcaattctta ctaatgatga ttttgattcc aagaataaaa 11100
aatttaatcc ataatgactt atcaattcaa acaaccacac aaagtttttt agtggaagct 11160aatttaatcc ataatgactt atcaattcaa acaaccacac aaagtttttt agtggaagct 11160
ctaagagcta tcacttttat taaatcaaat ggtttagatc attctatcct aacaaagtgg 11220ctaagagcta tcacttttat taaatcaaat ggtttagatc attctatcct aacaaagtgg 11220
tcaaattact atgataaaca aatcgaagca ttttcacagc gataccactt agacgctata 11280tcaaattact atgataaaca aatcgaagca ttttcacagc gataccactt agacgctata 11280
atggatagca taagtgtaag catccgatat tgtgcacccc ttctcttatt atggtttgga 11340atggatagca taagtgtaag catccgatat tgtgcacccc ttctcttatt atggtttgga 11340
tcaaaagaag ttatcaccgg aaatttaaca ctcggaggct tattagggtt tagcagctta 11400tcaaaagaag ttatcaccgg aaatttaaca ctcggaggct tattagggtt tagcagctta 11400
ggaacatctt tcttgttgcc gattgcttct ttaataacag gcatgcaaca atttcaattg 11460ggaacatctt tcttgttgcc gattgcttct ttaataacag gcatgcaaca atttcaattg 11460
gtcggtgaca cttttgaacg aatgcaagat gttatggaaa ctgagcccga acaaatcaac 11520gtcggtgaca cttttgaacg aatgcaagat gttatggaaa ctgagcccga acaaatcaac 11520
caaacttcaa taattgaaac tgaactatca aaacaagata taaaacttga aaatgtcaca 11580caaacttcaa taattgaaac tgaactatca aaacaagata taaaacttga aaatgtcaca 11580
tttacacatc atagcttaca tattcttaaa gaagtttcat taaacattaa gtcaggtact 11640tttacacatc atagcttaca tattcttaaa gaagtttcat taaacattaa gtcaggtact 11640
aaattagctc tcgtaggccg tacaggtagt ggaaagacaa ctttatcaag aattatactg 11700aaattagctc tcgtaggccg tacaggtagt ggaaagacaa ctttatcaag aattatactg 11700
gggttataca aacccactaa gggaaaagta ttttatggtg aacaggactt gaagaattta 11760gggttataca aacccactaa gggaaaagta ttttatggtg aacaggactt gaagaattta 11760
aacctttacg agctccgaaa acaaatgggg gtcgtattac aagaaagctt tcttttcaat 11820aacctttacg agctccgaaa acaaatgggg gtcgtattac aagaaagctt tcttttcaat 11820
gatactattg caaacaatat agctggattt aaaagcttat ctcaggataa aattgaacaa 11880gatactattg caaacaatat agctggattt aaaagcttat ctcaggataa aattgaacaa 11880
gcagcaaaga gagtgcagtt acatgaagat ataataagaa tgccaatggg atataacaca 11940gcagcaaaga gagtgcagtt acatgaagat ataataagaa tgccaatggg atataacaca 11940
attatcgggg aaaatggcag tatgttatca ggagggcagc gtcagcgcat agcaatagca 12000attatcgggg aaaatggcag tatgttatca ggagggcagc gtcagcgcat agcaatagca 12000
agagctatcg tcgataaccc ttctgtagtc attttagatg aaataacaag taacttggat 12060agagctatcg tcgataaccc ttctgtagtc attttagatg aaataacaag taacttggat 12060
acattaacag agcatgaaat tgacgaatac tttgcaaaat caaatattac ccgtattgta 12120acattaacag agcatgaaat tgacgaatac tttgcaaaat caaatattac ccgtattgta 12120
ataactcatc gtcttttaag tagccaagac tctgatttaa tagtggtatt agatcaagga 12180ataactcatc gtcttttaag tagccaagac tctgatttaa tagtggtatt agatcaagga 12180
aaaatagtcg aaaaaggaaa acatcaagag ttattagaga aaaagggata ctattataac 12240aaaatagtcg aaaaaggaaa acatcaagag ttattagaga aaaagggata ctattataac 12240
ttatggataa aacaagtagg ggatagacag aaagctacgc tgcaaaagcc ctttttcctc 12300ttatggataa aacaagtagg ggatagacag aaagctacgc tgcaaaagcc ctttttcctc 12300
aatgagcaaa ctggcaaaac ttga 12324aatgagcaaa ctggcaaaac ttga 12324
<210> 2<210> 2
<211> 48<211> 48
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 2<400> 2
taacacatgc ctcagctgcc taattgacat tgttatactt agatggcg 48taacacatgc ctcagctgcc taattgacat tgttatactt agatggcg 48
<210> 3<210> 3
<211> 40<211> 40
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 3<400> 3
taagtttata ccgcatatac cctacgtaag gtctcgttta 40taagtttata ccgcatatac cctacgtaag gtctcgttta 40
<210> 4<210> 4
<211> 40<211> 40
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 4<400> 4
ggtatatgcg gtataaactt atgagaattc gagacaaggt 40ggtatatgcg gtataaactt atgagaattc gagacaaggt 40
<210> 5<210> 5
<211> 40<211> 40
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 5<400> 5
atttacagag ggagaaaaaa atgagtattt caatattaaa 40atttacagag ggagaaaaaa atgagtattt caatattaaa 40
<210> 6<210> 6
<211> 40<211> 40
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 6<400> 6
ttttttctcc ctctgtaaat tttaaacaat catactacac 40ttttttctcc ctctgtaaat tttaaacaat catactacac 40
<210> 7<210> 7
<211> 43<211> 43
<212> DNA<212> DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 7<400> 7
tctaaccgca ttagtaccag ttcaagtttt gccagtttgc tca 43tctaaccgca ttagtaccag ttcaagtttt gccagttttgc tca 43
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210173000.6A CN114457102B (en) | 2022-02-24 | 2022-02-24 | Gene expression cassette for encoding secreted Mersacidin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210173000.6A CN114457102B (en) | 2022-02-24 | 2022-02-24 | Gene expression cassette for encoding secreted Mersacidin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114457102A true CN114457102A (en) | 2022-05-10 |
| CN114457102B CN114457102B (en) | 2023-12-26 |
Family
ID=81415670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210173000.6A Active CN114457102B (en) | 2022-02-24 | 2022-02-24 | Gene expression cassette for encoding secreted Mersacidin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114457102B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667991A (en) * | 1994-09-12 | 1997-09-16 | Hoechst Aktiengesellschaft | Recombinant mersacidin and a method for production |
| US20050164339A1 (en) * | 2004-01-12 | 2005-07-28 | Van Der Donk Willem A. | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics |
| WO2007036706A1 (en) * | 2005-09-27 | 2007-04-05 | Novacta Biosystems Limited | Variants of the lantibiotic mersacidin and their use |
| US20070117749A1 (en) * | 2004-03-26 | 2007-05-24 | Novacta Biosystems Limited | Production of mersacidin and its variants in SigH and/or mrsA negative bacillus host cells |
| CN110845586A (en) * | 2019-11-21 | 2020-02-28 | 重庆市畜牧科学院 | Secretory type grignard cyclic peptide and preparation method thereof |
| CN113354718A (en) * | 2021-06-21 | 2021-09-07 | 重庆市畜牧科学院 | Piranin precursor, expression cassette and preparation method thereof |
-
2022
- 2022-02-24 CN CN202210173000.6A patent/CN114457102B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667991A (en) * | 1994-09-12 | 1997-09-16 | Hoechst Aktiengesellschaft | Recombinant mersacidin and a method for production |
| US20050164339A1 (en) * | 2004-01-12 | 2005-07-28 | Van Der Donk Willem A. | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics |
| US20070117749A1 (en) * | 2004-03-26 | 2007-05-24 | Novacta Biosystems Limited | Production of mersacidin and its variants in SigH and/or mrsA negative bacillus host cells |
| WO2007036706A1 (en) * | 2005-09-27 | 2007-04-05 | Novacta Biosystems Limited | Variants of the lantibiotic mersacidin and their use |
| CN110845586A (en) * | 2019-11-21 | 2020-02-28 | 重庆市畜牧科学院 | Secretory type grignard cyclic peptide and preparation method thereof |
| CN113354718A (en) * | 2021-06-21 | 2021-09-07 | 重庆市畜牧科学院 | Piranin precursor, expression cassette and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| ANNA MARIA HERZNER等: "Expression of the Lantibiotic Mersacidin in Bacillus amyloliquefaciens FZB42", 《PLOS ONE》, vol. 6, no. 7, pages 4 - 5 * |
| HERZNER, A,M.等: "Bacillus sp. HIL-Y85/54728 mersacidin biosynthesis gene cluster (mrsK2, mrsR2, mrsF, mrsG, mrsE, mrsA, mrsR1, mrsD, mrsM and mrsT genes)", 《GENBANK DATABASE》, pages 250862 * |
| SARAVANAN R等: "Mining the Genome of Bacillus velezensis VB7 (CP047587) for MAMP Genes and Non-Ribosomal Peptide Synthetase Gene Clusters Conferring Antiviral and Antifungal Activity", 《MICROORGANISMS》, vol. 9, no. 12, pages 1 - 18 * |
| SUKUMAR CHATTERJEE等: "Mersacidin, a new antibiotic from bacillus fermentation, isolation, purification and chemical characterization", 《THE JOURNAL OF ANTIBIOTICS》, vol. 45, no. 6, pages 832 - 838 * |
| 程跃娟: "多粘类芽孢杆菌HY96-2的全基因组测序分析与生防机制的探索", 《中国优秀硕士学位论文全文数据库》, no. 2020, pages 046 - 277 * |
| 黄大野;曹春霞;张亚妮;王开梅;饶万中义;周荣华;杨自文;: "枯草芽孢杆菌NBF809防治番茄棒孢叶斑病研究", 《中国蔬菜》, no. 12, pages 46 - 50 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114457102B (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040106564A1 (en) | Use of slpi for treating chronic inflammatory intestinal diseases | |
| CN113755517B (en) | Construction method and application of SLCG _5407 gene modified streptomyces lincolnensis | |
| CN107312760B (en) | N-acyl homoserine lactonase and medicine thereof | |
| US20160279175A1 (en) | Methods for reducing development of resistance to antibiotics | |
| CN108794635B (en) | A kind of bovine lactoferrin peptide-human lysozyme fusion protein, gene and application thereof | |
| CN111411054B (en) | Lactococcus lactis expressing antimicrobial peptide gene | |
| CN111333713B (en) | Lactobacillus plantarum expressing antimicrobial peptide gene | |
| CN114540385A (en) | Method for producing lysostaphin by using escherichia coli | |
| CN101848723A (en) | Bacteriocin inducer peptides | |
| CN102329766A (en) | Recombination food-grade lactic acid bacterium capable of being used for preventing or treating human ulcerative colitis as well as preparation method and application of recombination food-grade lactic acid bacterium | |
| CN107312095A (en) | A kind of Melittin of antibacterial peptide LL 37 and its application and the preparation method in bacillus subtilis | |
| CN106520802A (en) | GAD gene for increasing stress tolerance of lactic acid bacteria and application thereof | |
| CN106366172A (en) | Bigeminal peptide Cec Md2ys, preparation method and application | |
| CN113354718B (en) | A kind of penithin precursor, expression cassette and preparation method thereof | |
| CN114457102B (en) | Gene expression cassette for encoding secreted Mersacidin and preparation method thereof | |
| CN110172433A (en) | It is a kind of produce pig's epidermal growth factor recombined bacillus subtilis engineering bacteria and application | |
| CN101851620B (en) | Method for producing FGFs by using edible and medicinal fungi | |
| CN104447976B (en) | One boar derived antimicrobial peptide cecropin P1 mutant and its preparation method and application | |
| CN107475222A (en) | The heat-resisting human lysozyme of genetic engineering transformation | |
| CN103333912A (en) | Method for implementing constitutive expression of plectasin derivative MP1102 in Pichia pastoris | |
| CN105968179A (en) | Fish-source antibacterial peptide pleurocidin mutant and application thereof | |
| CN110845586A (en) | Secretory type grignard cyclic peptide and preparation method thereof | |
| CN116196393A (en) | Application of antibacterial peptide AP138 in preparation of antibacterial drugs | |
| CN108752431A (en) | Heterozygous antibacterial peptide Mel-MytB and its application | |
| CN100436576C (en) | Nattokinase and its coding gene and clone and expressing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |